APA (7th ed.) Citation

M, M., Z, L., TP, V., JM, S., A, V., A, M., . . . C, H. (2026). Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2502849. https://doi.org/10.1200/JCO-25-02849

Chicago Style (17th ed.) Citation

M, Matasar, et al. "Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2026: JCO2502849. https://doi.org/10.1200/JCO-25-02849.

MLA (9th ed.) Citation

M, Matasar, et al. "Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2026, p. JCO2502849, https://doi.org/10.1200/JCO-25-02849.